Retrophin

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On Thursday, May 06, Retrophin (NASDAQ:TVTX) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Retrophin Earnings Preview

Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021 Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021

Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases

Retrophin Completes Acquisition of Orphan Technologies

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and December:

Retrophin to Present at Upcoming Investor Conferences

Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript

Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21

Retrophin Reports Third Quarter 2020 Financial Results

Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy?

Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

Retrophin Announces Agreement to Acquire Orphan Technologies

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Retrophin to Report Third Quarter 2020 Financial Results

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,750 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 37,500 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 21,250 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Retrophin’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Retrophin in accordance with Nasdaq Listing Rule 5635(c)(4).

Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. The Company and its collaborators will also feature encore presentations of preclinical data supporting the potential for sparsentan to protect kidney function in additional rare glomerular diseases. ASN Kidney Week 2020 Reimagined is being held virtually October 19–25, 2020.

Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined

Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021

Retrophin Reports Second Quarter 2020 Financial Results

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SAN DIEGO, July  16, 2020  (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Retrophin to Report Second Quarter 2020 Financial Results

Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Retrophin (RTRX) Looks Good: Stock Adds 5.8% in Session

SAN DIEGO, June  19, 2020  (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET.

Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

SAN DIEGO, June  08, 2020  (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin. The gross proceeds from the offering are expected to be approximately $100.8 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on June 11, 2020, subject to customary closing conditions. In addition, Retrophin has granted the underwriters for the offering a 30-day option to purchase up to an additional 975,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Retrophin Announces Pricing of Public Offering of Common Stock

SAN DIEGO, June  08, 2020  (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. All of the shares are being offered by Retrophin. In addition, Retrophin intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Retrophin Announces Proposed Public Offering of Common Stock

Retrophin's (RTRX) CEO Eric Dube on Q1 2020 Results - Earnings Call Transcript

Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Retrophin Stock (RTRX)